Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT06932471 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: MY008211A tablets

Sponsor

Wuhan Createrna Science and Technology Co., Ltd